SEARCH RESULTS

286 RESULTS

QALSODY™

THERAPEUTICS Biogen IONIS Pharmaceuticals Tofersen BIIB067 Ionis-SOD1Rx ASO1 DNA/RNA-based Other In January 2016, Biogen and Ionis began a Phase 1/2 safety trial in SOD1-ALS. The study enrolled 84 people who received single or multiple ascending doses by intrathecal i

PAPER Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, Van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.

N Engl J Med. 2020 Jul 9;383(2):109-119. PubMed: 32640130

Current Filters

  • Date Range : Jul 2020 to Jul 2020 x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE